Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766454 · ClinicalTrials.gov registry record
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 1,104
- Enrollment target
NCT00766454: Completed study, sponsored by Wake Forest University Health Sciences.
NCT00766454 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 1,104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00766454 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 1,104 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at urine and blood samples in women with newly diagnosed breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- GENETIC mutation analysis
- GENETIC DNA analysis
- GENETIC polymorphism analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,104 participants |
| Start Date | 1998-11 |
| Est. Completion | 2010-01 |
What the finished NCT00766454 record still lists
NCT00766454 is an observational study that tracks outcomes without assigning an intervention. Its 1,104 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00766454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00766454 about?
NCT00766454 is a clinical study titled "Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer". RATIONALE: Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at urine and blood samples in women with newly diagnosed breast cancer.
What is the current status of trial NCT00766454?
This trial is currently completed. The enrollment target is 1,104 participants. The study started on 1998-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00766454?
The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), mutation analysis (GENETIC), DNA analysis (GENETIC), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00766454?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia